These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24053621)

  • 1. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.
    Pinsky PF; Parnes HL; Andriole G
    BJU Int; 2014 Feb; 113(2):254-9. PubMed ID: 24053621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
    Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
    de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
    Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
    Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.
    Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G
    BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
    Pinsky PF; Prorok PC; Yu K; Kramer BS; Black A; Gohagan JK; Crawford ED; Grubb RL; Andriole GL
    Cancer; 2017 Feb; 123(4):592-599. PubMed ID: 27911486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
    Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening.
    Pierre-Victor D; Parnes HL; Andriole GL; Pinsky PF
    Urology; 2021 Sep; 155():62-69. PubMed ID: 34186135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
    de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
    Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Barocas DA; Grubb R; Black A; Penson DF; Fowke JH; Andriole G; Crawford ED
    Cancer; 2013 Jun; 119(12):2223-9. PubMed ID: 23559420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.